VSTM logo

VSTM
Verastem Inc

24,069
Mkt Cap
$479.62M
Volume
11,160.00
52W High
$11.25
52W Low
$4.01
PE Ratio
-1.64
VSTM Fundamentals
Price
$5.46
Prev Close
$5.40
Open
$5.49
50D MA
$5.75
Beta
1.34
Avg. Volume
2.26M
EPS (Annual)
-$3.02
P/B
7.42
Rev/Employee
$303,078.43
$417.24
Loading...
Loading...
News
all
press releases
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI FAKZYNJA CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine...
Business Wire·1d ago
News Placeholder
More News
News Placeholder
Verastem (VSTM) Projected to Post Earnings on Thursday
Verastem (NASDAQ:VSTM) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...
MarketBeat·1d ago
News Placeholder
Verastem, Inc. (NASDAQ:VSTM) Receives Average Rating of "Moderate Buy" from Analysts
Verastem, Inc. (NASDAQ:VSTM - Get Free Report) has been given an average rating of "Moderate Buy" by the nine brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a bu...
MarketBeat·7d ago
News Placeholder
Torray Investment Partners LLC Purchases Shares of 216,387 Verastem, Inc. $VSTM
Torray Investment Partners LLC purchased a new stake in shares of Verastem, Inc. (NASDAQ:VSTM - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange...
MarketBeat·8d ago
News Placeholder
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a...
Business Wire·8d ago
News Placeholder
Verastem's (VSTM) Buy Rating Reaffirmed at BTIG Research
BTIG Research reissued a "buy" rating and set a $19.00 target price on shares of Verastem in a research note on Monday...
MarketBeat·11d ago
News Placeholder
Verastem (NASDAQ:VSTM) Trading Down 4.1% - Here's Why
Verastem (NASDAQ:VSTM) Stock Price Down 4.1% - Here's Why...
MarketBeat·11d ago
News Placeholder
Verastem (NASDAQ:VSTM) Trading Up 7.6% - What's Next?
Verastem (NASDAQ:VSTM) Shares Up 7.6% - What's Next...
MarketBeat·18d ago
News Placeholder
Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of Verastem from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·20d ago
News Placeholder
Verastem (NASDAQ:VSTM) Earns "Buy" Rating from BTIG Research
BTIG Research reiterated a "buy" rating and issued a $19.00 target price on shares of Verastem in a research report on Friday...
MarketBeat·21d ago
<
1
2
...
>

Latest VSTM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.